Loxo Oncology (LOXO) Reports In-Line Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Loxo Oncology (LOXO) Reports In-Line Q3 Loss
November 10, 2015 6:45 AM EST
STAMFORD, Conn., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at three upcoming conferences.
Details of the conferences are as follows:
Stifel...
More
November 10, 2015 6:45 AM EST
STAMFORD, Conn., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported financial results for the third quarter ended September 30, 2015 and provided an update on its pipeline. Loxo Oncology will not be conducting a conference call in conjunction with this earnings release.
In the third quarter we made tremendous progress with LOXO-101, executing ahead of plan, said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. Our Phase 1 trial continues to... More
